Revenue Recognition (Tables)

3 Months Ended

Mar. 31, 2021

Revenue from Contract with Customer [Abstract]

Segment information is as follows (in thousands):


	Three months ended March 31, 2021						Three months ended March 31, 2020
	Performance Enzymes		Novel Biotherapeutics		Total		Performance Enzymes		Novel Biotherapeutics		Total
Major products and service:
Product Revenue	$	10,226	$	—	$	10,226	$	5,100	$	—	$	5,100
Research and development revenue	4,003		3,803		7,806		5,774		3,796		9,570
Total revenues	$	14,229	$	3,803	$	18,032	$	10,874	$	3,796	$	14,670

Primary geographical markets:
Americas	$	2,871	$	2,058	$	4,929	$	2,999	$	2,226	$	5,225
EMEA	4,537		1,745		6,282		4,401		1,570		5,971
APAC	6,821		—		6,821		3,474		—		3,474
Total revenues	$	14,229	$	3,803	$	18,032	$	10,874	$	3,796	$	14,670

Contract with customer

The following table presents balances of contract assets, unbilled receivables, contract costs, and contract liabilities (in thousands):


	March 31, 2021		December 31, 2020
Contract assets	$	5,143	$	4,526
Unbilled receivables	$	11,298	$	10,942
Contract costs	$	58	$	90
Contract liabilities: deferred revenue	$	4,797	$	4,791

We recognized the following revenues (in thousands):


	Three months ended March 31,
Revenue recognized in the period for:	2021		2020
Amounts included in contract liabilities at the beginning of the period:
Performance obligations satisfied	$	862	$	57
Changes in the period:
Changes in the estimated transaction price allocated to performance obligations satisfied in prior periods	$	24	$	(643)
Performance obligations satisfied from new activities in the period - contract revenue	17,146		15,256
Total revenues	$	18,032	$	14,670

Performance obligation, expected timing of satisfaction

The following table includes estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied or partially unsatisfied at the end of the reporting periods. The estimated revenue does not include contracts with original durations of one year or less, amounts of variable consideration attributable to royalties, or contract renewals that are unexercised as of March 31, 2021.

The balances in the table below are partially based on judgments involved in estimating future orders from customers subject to the exercise of material rights pursuant to respective contracts as of March 31, 2021 (in thousands):


	Remainder of 2021		2022		2023		2024 and Thereafter		Total
Product Revenue	$	400	$	67	$	431	$	1,923	$	2,821
Research and development revenue	1,430		—		546		—		1,976
Total revenues	$	1,830	$	67	$	977	$	1,923	$	4,797